Variable drug responses among malignant cells within individual tumors may represent a barrier to their eradication using chemotherapy. Carcinoma cells expressing mesenchymal markers resist conventional and epidermal growth factor receptor (EGFR)-targeted chemotherapy. In this study, we evaluated whether mesenchymal-like sub-populations within human squamous cell carcinomas (SCCs) with predominantly epithelial features contribute to overall therapy resistance. We identified a mesenchymal-like subset expressing low E-cadherin (Ecad-lo) and high vimentin within the upper aerodigestive tract SCCs. This subset was both isolated from the cell lines and was identified in xenografts and primary clinical specimens. The Ecad-lo subset contained more lowturnover cells, correlating with resistance to the conventional chemotherapeutic paclitaxel in vitro. Epidermal growth factor induced less stimulation of the mitogenactivated protein kinase and phosphatidylinositol-3-kinase pathways in Ecad-lo cells, which was likely due to lower EGFR expression in this subset and correlated with in vivo resistance to the EGFR-targeted antibody, cetuximab. The Ecad-lo and high E-cadherin subsets were dynamic in phenotype, showing the capacity to repopulate each other from single-cell clones. Taken together, these results provide evidence for a low-turnover, mesenchymal-like sub-population in SCCs with diminished EGFR pathway function and intrinsic resistance to conventional and EGFR-targeted chemotherapies.
Introduction
The inability to eradicate squamous cell carcinomas (SCCs) of the upper aerodigestive tract, including those of the head and neck (HNSCC) and esophagus, with chemotherapy alone is a feature shared with most other malignancies. Drug therapy for advanced-stage HNSCC has benefited from two recent advances: inclusion of paclitaxel in conventional chemotherapy regimens (Posner et al., 2007; Vermorken et al., 2007) and introduction of the epidermal growth factor receptor (EGFR)-targeted antibody cetuximab into clinical use (Herbst et al., 2005; Bonner et al., 2006) . Although these agents can produce dramatic responses, cancer recurrence is inevitable without the addition of other therapeutic modalities, and treatment failures are common even with the use of combined modalities. Thus, identifying and targeting minority SCC sub-populations with intrinsic resistance to these two agents is an appealing strategy for tumor eradication.
Epithelial-to-mesenchymal transition (EMT) generates phenotypic heterogeneity within SCCs, and is one potential basis for defining sub-populations with intrinsic drug resistance. The hallmark of EMT is loss of cell surface E-cadherin, which accompanies disassembly of adherens junctions, acquired motility and expression of mesenchymal markers including vimentin, N-cadherin and fibronectin (Christiansen and Rajasekaran, 2006; Hugo et al., 2007) . The EMT program is coordinated by multiple transcription factors, including the Twist, Snail and Zeb families (Cano et al., 2000; Peinado et al., 2007; Ansieau et al., 2008) . Originally characterized as an embryological process that drives cell migration and diversifies phenotype, EMT concepts remain controversial in application to cancer biology. Although recognizable in carcinoma lines, the dramatic phenotypic shifts of EMT are generally not observed to a similar extent in vivo (Tarin et al., 2005) , and it is doubtful whether carcinomas ever fully acquire mesenchymal features to parallel events during development. However, a range of mesenchymal traits do exist across SCCs, and we therefore favor the label 'mesenchymal-like' to designate phenotypes arising from EMT in malignancy.
Thus far, drug resistance arising from EMT has been assessed mainly by comparing cell lines possessing or lacking prominent expression of mesenchymal markers, based on the premise that this property distinguishes two subtypes of tumors. Several studies have correlated mesenchymal-like traits with higher overall resistance to conventional cytotoxic chemotherapies (Yang et al., 2006; Wang et al., 2009) and EGFR inhibitors (Thomson et al., 2005; Yauch et al., 2005; Fuchs et al., 2008) . However, carcinomas rarely fall cleanly into dichotomous epithelial or mesenchymal-like categories in vivo, and instead, show either predominantly epithelial features or a spectrum of mixed epithelial and mesenchymal-like differentiation (Strauss et al., 2009) . It is presently unclear whether the intrinsic drug resistance in 'mesenchymal' carcinoma lines is actually attributable to discrete mesenchymal-like sub-populations within them, and whether comparable populations in vivo have a similar role.
In this study, we identified and isolated a minority mesenchymal-like sub-population from SCCs bearing predominantly epithelial features. Distinctive growth and EGFR signaling properties are identified in this subset and correlated with intrinsic resistance to paclitaxel and cetuximab in vitro. In addition, cetuximab resistance of these cells is evaluated in vivo using direct xenografts of human primary tumors. To clarify the developmental relationship between the epithelial and mesenchymal-like sub-populations, the phenotypic stability of each is tracked at a clonal level.
Results
SCCs contain distinct epithelial and mesenchymal-like sub-populations in vitro and in vivo Initially, the variability in epithelial versus mesenchymal-like differentiation was defined in a panel of 10 SCC cell lines, which were segregated into three general patterns based on E-cadherin and vimentin staining. One end of the spectrum is represented by the SCC15, TE12 and SCC13 cell lines, which shows diffuse E-cadherin expression and limited or no vimentin staining (Supplementary Figure S1A ). TE1, SCC9, OCTT2 and TE9 cells represented an intermediate pattern, with distinct E-cadherin and vimentin-positive populations, and in the case of TE9, a sizeable subset expressing both markers (Supplementary Figure S1B) . The other extreme is exemplified by the SCC4, TE8 and HCE4 cell lines, which show diffuse vimentin staining and minimal E-cadherin-expressing cells (Supplementary Figure S1C ).
To facilitate a study of mesenchymal-like subsets in tumors with predominantly epithelial features, we selected two HNSCC lines (SCC9 and OCTT2) containing minority sub-populations sizeable enough to isolate. These lines seemed heterogeneous in culture, with clustered epithelial-like cells interspersed with fusiform mesenchymal-like morphologies (Figure 1a , left panels). Both lines mostly comprised non-overlapping high E-cadherin (Ecad-hi)/ low vimentin (Vim-lo) and low E-cadherin (Ecad-lo)/high vimentin (Vim-hi) populations ( Figure 1a , right panels). The minimal overlap between these phenotypes was confirmed by segregating each line into Ecad-hi and Ecad-lo groups (Figure 1b , top) by fluorescence-activated cell sorting (FACS) and showing vimentin staining reciprocal to E-cadherin expression in sorted subsets (Figure 1b, bottom) . To confirm that Ecad-lo cells possess mesenchymal-like differentiation, gene expression profiles of Ecad-hi and Ecad-lo populations were compared. SCC9 and OCTT2 Ecad-lo cells upregulated multiple genes associated with EMT (Figure 1c , left) and also downregulated genes characteristic of epithelial phenotypes (Figure 1c , right). These findings confirmed that FACS purification of Ecad-hi and Ecad-lo cells was a valid method of segregating the epithelial and mesenchymal-like subsets. Thus, the terms 'Ecad-hi' and 'Ecad-lo' are subsequently used interchangeably with 'epithelial' and 'mesenchymallike' in reference to SCC9 and OCTT2 cells.
Mesenchymal-like sub-populations were identified in vivo using dual immunohistochemistry (IHC) staining for E-cadherin and vimentin. Mouse xenografts of the SCC9 line contained a small vimentin-positive subset with fusiform morphology, distinct from the E-cadherinpositive majority (Figure 1d , top left). To enhance the visual contrast between vimentin and E-cadherin staining, chromogens were digitally converted to red and green pseudocolors, respectively (Figure 1d , bottom left). A vimentin-expressing sub-population was also observed in the original human primary tumor from which the OCTT2 line was derived (Figure 1d , middle), although detection of non-malignant stromal cells by the human-specific vimentin antibody could not be excluded in this study. For this reason, a similar vimentin-positive subset was sought and identified in a direct xenograft of this primary tumor (Figure 1d , right). In this study mouse passage is expected to deplete all non-malignant human cells, and use of human-specific antibody prevented labeling of mouse-derived stromal cells within the xenografts. The malignant potential of the mesenchymal-like subset was shown by comparing in vivo growth of sorted Ecad-hi versus Ecad-lo cells from the OCTT2 cell line (Supplementary Figure S2 ). As xenografts, these purified subsets showed no major differences in latency, growth, histology or distribution of mesenchymal-like cells in mature tumors. The broad in vivo relevance of the vimentin-positive sub-population is underscored by SCC9 and OCTT2 tumors representing opposites in the spectrum of HNSCC grades, from well differentiated to poorly differentiated (Supplementary Figure S3 ).
The mesenchymal-like subset contains more low-turnover cells
To determine whether the mesenchymal-like sub-population had altered growth features, proliferation of Ecad-hi and Ecad-lo SCC9 cells was compared by methylthiazonletetrazolium (MTT) assay, which showed slower growth in the Ecad-lo compartment (Figure 2a ). Reduced growth of Ecad-lo cells coincided with a higher proportion in G0/G1 phase by cell-cycle analysis ( Figure 2b ) and double the percentage in resting G0
Evidence of drug-resistant mesenchymal subset D Basu et al Figure 2c ). The turnover characteristics of Ecad-hi and Ecad-lo sub-populations were compared over an extended period, based on dilution of the fluorescent membrane label, PKH-67, with ongoing cell division. After uniform PKH-67 labeling, SCC9 cells were grown in culture for 9 days to create a broad distribution of PKH-67 intensity (Figure 2d ). Low-and high-turnover subsets were defined as populations with the 10% highest and 10% lowest PKH-67 label, respectively. Low-turnover (high label-retaining) SCC9 cells contained over fivefold more Ecad-lo cells relative to highturnover (low label-retaining) cells. Taken together, these results indicated that the mesenchymal-like subpopulation contains a larger proportion of low-turnover cells and is less proliferative overall.
The mesenchymal-like sub-population shows intrinsic resistance to paclitaxel To assess whether diminished growth of the mesenchymal-like subset correlates with paclitaxel resistance, FACS-segregated Ecad-hi and Ecad-lo cells were compared for drug-induced growth inhibition ( Figure 3a ). The half-maximal growth inhibitory concentration for Ecad-lo cells was 2-log higher in SCC9 and 1.5-log higher in OCTT2, relative to Ecad-hi cells, using a 4 h drug exposure. Prolonging the drug exposure time to 48 h minimally impacted this difference in halfmaximal growth inhibitory concentration (IC50) for OCTT2 and diminished it to a still-significant 0.75 log for SCC9 (Supplementary Figure S4 ). Unsorted SCC9 cells also showed evidence of paclitaxel resistance in the Ecad-lo subset, which became enriched from 18 to 50% in cultures after brief drug exposure ( Figure 3b Evidence of drug-resistant mesenchymal subset D Basu et al elevated intrinsic resistance to killing by paclitaxel, but also maintained growth potential post therapy. SCC9 cultures were tracked by video to distinguish whether paclitaxel enriched the Ecad-lo subset by selectively depleting Ecad-hi cells or by causing differentiation toward the mesenchymal-like phenotype. Videos of untreated cells show rapidly dividing cells of epithelial morphology against slowly proliferative but more migratory cells of mesenchymal appearance (Video 1). In treated cells, cell death localized to areas with epithelial morphology, sparing regions with mesenchymal-like differentiation (Video 2 and Figure 3d ). This finding showed that the Ecad-hi subset was selectively killed by paclitaxel, and suggested its depletion as the major mechanism behind relative expansion of the Ecad-lo sub-population.
Decreased EGFR expression in the mesenchymal-like subset correlates with diminished regulation of mitogenactivated protein kinase (MAPK)/phosphatidylinositol-3-kinase (PI3K) pathways by EGFR ligand The EGFR-targeted antibody cetuximab is another key agent in clinical use against SCCs. To assess potential responsiveness of the mesenchymal-like sub-population to EGFR targeting, we compared the integrity of EGFR signaling pathways between the Ecad-lo and Ecad-hi subsets. Flow cytometry (FC) of SCC9 and OCTT2 lines identified decreased surface EGFR expression in the Ecad-lo versus Ecad-hi subsets (Figure 4a , left/middle). Reduced surface EGFR expression in the Ecad-lo subset was also shown in vivo by analyzing disaggregated xenografts of the tumor from which the OCTT2 line was derived (Figure 4a, right) . This reduction in surface EGFR corresponded with diminished total EGFR levels in the mesenchymal-like subset, as shown by immunofluorescence staining (Supplementary Figure S5A) , FC of permeabilized cells (Supplementary Figure S5B ) and western blot (Supplementary Figure S5C) .
We assessed whether EGFR downregulation in Ecad-lo cells corresponded with diminished capacity of the receptor to regulate the downstream PI3K and MAPK pathways. Minimal activation of both ERK (Figure 4b ) and AKT (Figure 4c ) was seen in serum-starved vimentinpositive SCC9 cells on the addition of epidermal growth factor (EGF), in contrast to prominent activation of both molecules by ligand in vimentin-negative cells. Co-staining for E-cadherin in place of vimentin confirmed a pattern of selective ERK/AKT activation in the Ecad-hi subset by EGFR ligand (Supplementary Figure S6 ). Taken together, these results provide evidence that the MAPK and PI3K pathways are uncoupled from regulation by EGFRspecific ligands in Ecad-lo cells, most likely as a consequence of decreased EGFR expression in this subset.
The mesenchymal-like sub-population shows intrinsic resistance to cetuximab in vitro and in vivo Reduced signaling through EGFR in the Ecad-lo subset predicted diminished responsiveness to cetuximab. Accordingly, cetuximab showed greater activity against Ecad-hi cells in both SCC9 and OCTT2 (Figure 5a ). To assess whether the mesenchymal-like subset was cetuximab-resistant in vivo, mice xenografted with the tumor of origin for the OCTT2 cell line were treated with cetuximab. Partial regression of established tumors was observed over 12 days, during which time salinetreated controls grew rapidly (Figure 5b ). Dual-label IHC staining of treated tumors showed a marked increase in vimentin-expressing areas relative to controls (Figure 5c, first row) , and visual contrast between the dual sub-populations was enhanced by pseudocoloring the chromogens (second row). Dual IHC-stained tumors were analyzed to quantify the increase in vimentin staining area by comparing wide fields of treated and untreated tumors (third row). Calculating relative sizes of Vim-hi versus Vim-lo areas (mapped in red and green, fourth row) showed a greater-than-twofold increase in Vim-hi regions with cetuximab treatment (Figure 5d ). These results strongly suggest that selective targeting of the Ecad-hi sub-population with cetuximab enriched the mesenchymal-like subset, either through the depletion of epithelial cells and/or increasing their differentiation toward a mesenchymal-like phenotype.
Epithelial and mesenchymal-like phenotypes are reversible at a clonal level The observed therapy resistance of the Ecad-lo cells warranted investigation of their capacity to repopulate Ecad-hi components of tumors. To clarify developmental relationships between these two sub-populations, the phenotypic stability of each was tracked using clones of single SCC9 cells. Morphologically homogeneous colonies arising from single Ecad-hi or Ecad-lo cells were confirmed for purity based on exclusive E-cadherin or vimentin staining, and similar colonies were expanded and tracked for development of heterogeneity. Epithelial colonies arising from Ecad-hi cells rapidly reconstituted a mesenchymal-like subset, detectable within 2 weeks of plating at clonal density (Figure 6a ). Mesenchymal-like colonies from Ecad-lo cells showed phenotypic stability on initial expansion. However, these colonies reconstituted the epithelial subset on further growth, with early evidence of a small Ecad-hi sub-population appearing at 4 weeks and expansion of this subset noted by 8 weeks (Figure 6b ). These results indicated that the mesenchymal-like sub-population is not terminally differentiated, and suggested that it retains the plasticity to reconstitute other malignant subsets post therapy.
Discussion
In this study we have shown that mesenchymallike malignant sub-populations contribute to chemotherapy resistance in SCCs with predominantly epithelial differentiation. Previous studies correlated drug resistance in carcinoma lines with increased expression of mesenchymal markers (Thomson et al., 2005; Yauch et al., 2005; Yang et al., 2006; Frederick et al., 2007; Shrader et al., 2007; Ghoul et al., 2009) . However, analyzing lines as total populations does not account for Evidence of drug-resistant mesenchymal subset D Basu et al the possible presence of epithelial and mesenchymal-like subsets, which may make disparate contributions to overall drug resistance. We suggest that SCCs in vivo typically do not possess uniformly epithelial or mesenchymal-like phenotypes; accordingly, the heterogeneity defined in this study in SCC cell lines was maintained by (Mandal et al., 2008) . At the other end of the spectrum, cell lines with Ecad-hi expression can still contain small vimentinexpressing subsets (Supplementary Figure S1) , and we note the same observation in xenografts of human HNSCC specimens (unpublished data). Nevertheless, it is unlikely that the precise markers used in this study to define the treatment resistant sub-population will identify subsets with similar properties across all SCCs. We speculate that more subtle phenotypic transitions sharing key molecular traits with the ones documented in this study may be a basis for intrinsic treatment resistance across many SCC tumors. In this study, intrinsic paclitaxel resistance of the mesenchymal-like sub-population seemed attributable to its slower growth. However, cytotoxic drug resistance after EMT is likely more than a direct function of growth rate and instead reflects the outcome of generegulatory programs with complex relationships with proliferation, differentiation and apoptosis. For Evidence of drug-resistant mesenchymal subset D Basu et al instance, a recent study showed that paclitaxel induces snail and slug, which, in addition to being transcription factor mediators of EMT, also repressed promoters of key molecules involved in p53-mediated apoptosis (Kurrey et al., 2009) . Thus, at least in vitro, paclitaxel likely depletes the epithelial subset by multiple mechanisms, and may also contribute to the enrichment of mesenchymal-like cells by promoting EMT. Similarly, adriamycin, a cytotoxic drug of differing mechanism, also enhances EMT and creates resistance to itself and other agents as a twist1-mediated phenomenon (Li et al., 2009b) .
Resistance to cetuximab in the Ecad-lo subset in this study likely arose from reduced EGFR expression and resulting loss of MAPK and PI3K pathway regulation by the receptor. This correlation contrasts with the lack of positive association between EGFR overexpression and clinical cetuximab sensitivity in HNSCC (Kalyankrishna and Grandis, 2006) . Our findings also differ from a study of hepatocellular carcinoma cell lines, wherein EGFR levels appeared independent of mesenchymal marker expression (Fuchs et al., 2008) . However, EGFR expression had thus far been compared against mesenchymal features using bulk lines, wherein overall receptor levels may not reflect those of any mesenchymal-like subsets they contain.
Known resistance mechanisms to EGFR-targeted therapies (Bianco et al., 2005; Cooper and Cohen, 2009 ) provide a context for understanding the cetuximab insensitivity observed in this study. A novel mechanism Figure 6 Dynamic reversibility of epithelial and mesenchymal-like phenotypes at a clonal level. (a) Ecad-hi SCC9 cells were plated at clonal dilution, and wells containing single colonies with pure epithelial morphology are identified after 1 week (top, Â 20) by staining for DAPI (blue), E-cadherin (green) and vimentin (red). Similar morphologically pure colonies were expanded and then stained at 2 weeks (bottom). (b) Ecad-lo SCC9 cells were plated at clonal dilution, and wells containing isolated colonies with pure mesenchymallike morphology are identified at 2 weeks and stained as in (a) (top row; Â 20, inset Â 10). Comparable colonies were expanded until epithelial areas initially appeared at 4 weeks (middle row) or fully repopulated after 8 weeks (bottom row). Bars ¼ 100 mm.
Evidence of drug-resistant mesenchymal subset D Basu et al for acquired cetuximab resistance is ligand-independent EGFR function through downregulation of surface receptor and elevated nuclear, cytoplasmic and total receptor levels (Li et al., 2009a) . This mechanism may partly explain the association in HNSCCs of EGFR gene amplification and poor prognosis (Chung et al., 2006; Temam et al., 2007) , but in this study the reduced surface and total EGFR in Ecad-lo cells argues against this explanation for their resistance. An alternative explanation is switching to other receptor tyrosine kinases to restore downstream survival and proliferation signals. For instance, EGFR and ErbB2 expression were noted to segregate to different regions within esophagus SCCs and thus might serve comparable functions in distinct sub-populations. In addition, EGFR downregulation and coordinate upregulation of ErbB2/ ErbB3 in HNSCC are described in response to the EGFRtargeted small molecule, gefitinib (Erjala et al., 2006) . Kinase switching to receptors outside the EGFR family is observed in mesenchymal-like cell lines of non-small-cell lung cancers (Thomson et al., 2005) and is a plausible mechanism in this study. Notably, the EGFR-activating mutations that sensitize non-small-cell lung cancer to gefitinib (Gazdar, 2009 ) are largely absent in HNSCC (Temam et al., 2007) , and thus sensitivity to this inhibitor is not anticipated in the face of cetuximab resistance. Traits of the mesenchymal-like sub-population in SCCs have implications in the wider discussion regarding origins of phenotypic heterogeneity within solid tumors. Specifically, it remains unclear how much intratumor heterogeneity arises from epigenetic differences versus genetic change driven by clonal evolution (Shackleton et al., 2009) . The ability of epithelial and mesenchymal-like subsets to reconstitute each other from single cell clones, as shown in this study, suggests that these phenotypes are distinguished primarily by epigenetic alterations and not genotypic selection. The cancer stem cell hypothesis is one framework for explaining how an epigenetically distinct sub-population may sustain tumor growth and resist drug therapy. In this study, we have elected not to frame the mesenchymal-like subset explicitly within controversial and evolving definitions of cancer stem cells; however, this subset appears to maintain malignant potential and does not represent a terminally differentiated phenotype. The sub-population in SCC may have functions analogous to the CD44 þ /CD24 À stem-like subset in breast carcinoma on the basis of sharing its mesenchymal-like gene expression profile (Mani et al., 2008) . If so, the in vitro plasticity of our sub-populations argues against a rigid developmental hierarchy originating with stem cells and ending in terminal differentiation, instead favoring the one wherein phenotypes are dynamic and sensitive to microenvironments. It is possible that the mesenchymallike subset in SCCs retains the phenotypic plasticity to repopulate other sub-populations post therapy.
In the context of our findings, promoting phenotypic reversal of Ecad-lo cells through mesenchymal-toepithelial transition may be a viable strategy for chemosensitization. In this study, pure mesenchymal-like clones of SCC lines showed initial resistance to mesenchymal-to-epithelial transition, but did restore the epithelial sub-population spontaneously after extended culture. Experimental maneuvers that both promote mesenchymal-to-epithelial transition and enhance drug sensitivity include downregulation of Notch (Wang et al., 2009 ), induction of Raf-kinase inhibitor protein (Wu and Bonavida, 2009 ), knockdown of zeb-1 (Haddad et al., 2009 ) and induction of miR-200 microRNA family members (Gregory et al., 2008; Adam et al., 2009; Li et al., 2009c) . Future studies will seek pharmacological strategies for both specifically targeting the mesenchymal-like sub-population in SCCs and promoting its phenotypic reversal.
Materials and methods

Cell lines and clinical specimens
Cell lines were maintained in 1:1 Dulbecco's modified Eagle and Ham's F12 media, with 400 ng/ml hydrocortisone and 10% fetal calf serum. Genetic purity of the cell lines was confirmed with an Identify Mapping Kit (Coriell Institute, Camden, NJ, USA). SCC9, SCC4 and SCC15 cells were obtained from the ATCC (CRL-1629 (CRL- , 1624 (CRL- , 1623 . TE12, SCC13, TE1, TE9, TE8 and HCE4 cell lines are described previously (Opitz et al., 1998; Okano et al., 2000) . The OCTT2 cell line was derived from a surgical specimen of an oral HNSCC in compliance with University of Pennsylvania Institutional Review Board-approved protocol #417200. Tumor cells purified from xenografts of this specimen were seeded at 5000 cells/cm 2 on mitomycin C-treated 3T3 fibroblasts and cultured as described previously (Rheinwald and Beckett, 1981) .
Animals and in vivo experiments
Non-obese diabetic/severe combined immunodeficient/interleukin-2 receptor g-chain-deficient mice were used in all experiments. The animals were bred and used at the Wistar Institute animal facility under protocols approved by the Institutional Animal Care and Use Committee. To generate xenografts from human SCC specimens, 1 mm tumor fragments were placed in subcutaneous pockets through flank incisions in anesthetized mice. Growth Factor Reduced Matrigel (BD, Franklin Lakes, NJ, USA) was added, and the incisions were closed with a suture. The xenografts were used before 10 in vivo passages, and the tumor volumes were measured as (length Â width Â thickness). Xenografts of SCC9 cells were generated by subcutaneous injection of 2 Â 10 6 cells in 100 ml Matrigel. For drug treatment, 1 mg cetuximab (Imclone, New York, NY, USA) or equivalent volume of saline control was injected intraperitoneally every 3 days.
Microscopy
Images obtained using Nikon TE2000 and E600 microscopes were processed with ImagePro-Plusv6.2 and ACT-1 software using uniform settings within each experiment. For video microscopy, SCC9 cells cultured in six-well plates were treated with paclitaxel or control dimethylsulfoxide. The drug was removed after 4 h, and the medium was supplemented with 20 mg/ml propidium iodide. Cell death (propidium iodide uptake) was monitored using a Nikon TE300 microscope configured with automated filter wheels and stage, and an environmental chamber. Three fields per well were captured at 10-min intervals and sequenced into video using ImagePro-Plus.
Evidence of drug-resistant mesenchymal subset D Basu et al
Immunofluorescence staining
Immunofluorescence staining was performed in 24-well plates or gelatin-coated glass chamber slides, as described previously (Smalley et al., 2005) . Antibodies of the following specificities were used: alexafluor488-E-cadherin (BD), phosphoERK1/2-Thr202/Tyr204 (pERK), phosphoAKT-Ser473 (pAKT; Cell Signaling, Danvers, MA, USA), vimentin (AnaSpec, Fremont, CA, USA) and vimentin (Dako, Carpinteria, CA, USA). Secondary antibodies included alexafluor488-antirabbit IgG, alexafluor594-antihuman IgG and alexafluor594-antirabbit IgG (Invitrogen, Carlsbad, CA, USA). Isotype-matched mouse and rabbit antibodies were used as controls. In signaling experiments, cells were serum-starved for 24 h before treatment with 200 ng/ml recombinant human EGF (Invitrogen) for 1 h.
FC, cell sorting, tumor cell purification from xenografts
A FACSAria (BD) sorter was used for FACS. FC was performed using a FACSCalibur instrument (BD) and analyzed using WinMDIv2.9. Dead cells were removed by exclusion of either propidium iodide or 7-amino-actinomycin-D-positive cells. Where required for intracellular staining, sorted cells were permeabilized with acetone, as described previously (Mancaniello and Carbonari, 2008) . Cell-cycle analysis was performed as described previously (Smalley et al., 2006) . FC staining (Fang et al., 2005) was performed with the following human specific antibodies: fluorescein isothiocyanate-Ki-67, allophycocyanin-E-cadherin (Biolegend, San Diego, CA, USA), phycoerythrin-vimentin (Abcam, Cambridge, MA, USA), fluorescein isothiocyanate-EGFR (Santa Cruz Biotech., Santa Cruz, CA, USA), fluorescein isothiocyanate mouse IgG 1,k control (BD), allophycocyanin mouse IgG 1 control and phycoerythrin mouse IgG 1 control (BD). PKH-67 labeling was performed according to the supplier protocol (Sigma, St Louis, MO, USA).
To FACS-purify tumor cells from xenografts, minced tumors were digested overnight at 4 o C in culture medium containing 2 mg/ml collagenase-I and 1 mg/ml collagenase-IV. Suspensions were passed through 40-mm filters and pretreated with rat antimouse CD16/32 (Fc-Block, BD). Mouse-derived cells were excluded by positive selection of human cells with mouse antihuman major histocompatibility class I (Abcam) and phycoerythrin-antimouse IgG F(ab) 2 secondary antibody (Sigma).
Dual-label IHC, processing of images
Formalin-fixed, paraffin-embedded specimens were cut into 5mm sections, and the antigens were retrieved by boiling for 15 min in the EDTA buffer (Lab Vision, Fremont, CA, USA). Staining was performed sequentially for E-cadherin and vimentin, using the Envision Detection Kit (Dako), followed by hematoxylin counterstain. Mouse antihuman E-cadherin (Dako) was used at 1:10 dilution and detected with 3 0 ,3diaminobenzidine. After re-quenching peroxidase activity, mouse antihuman vimentin (Dako) was used without dilution and detected using Vector VIP (V-VIP) chromogen (Vector, Burlingame, CA, USA). Specificity was confirmed using mouse IgG1 controls for each antibody. To generate pseudocolored images, IHC micrographs were processed using Adobe Photoshop CS2. Color ranges corresponding to 3 0 ,3-diaminobenzidine and V-VIP-stained areas were separated using histogram analysis and color-replaced with green and red, respectively. Images in each experiment were batch-processed with uniform color-replacement settings using Photoshop Bridge. Image-based quantitative analysis of E-cadherin versus vimentin staining areas was performed with ImagePro-Plus, using the Count/Size tool. Two color masks were created using color cube analysis to separate labeled components based on spectral distribution. The count tool was then used to quantify relative percentages of E-cadherin versus vimentin staining areas. The masks were copied to black backgrounds to create the displayed images. Batch processing ensured unbiased comparison of groups.
Clonogenicity, MTT assays Clonogenicity was measured by seeding six-well plates at 1,000 cells per well. After 7 days, colonies were stained with 0.5% crystal violet in 25% methanol and counted on high-resolution digital images. MTT assays were performed by seeding 3,000 cells per well (OCTT2) or 5,000 cells per well (SCC9) on 96-well plates, unless otherwise noted. Growth was quantified using a MTT Proliferation Kit (Invitrogen). Optical density in each well was measured at 590 nm (OD-590 nm), and values were normalized relative to OD-590 nm for non-treated controls in drug treatment experiments.
Gene expression profiling
In three independent experiments, Ecad-hi and Ecad-lo subpopulations were sorted, and RNA was extracted using an RNAeasy Kit (Qiagen, Valencia, CA, USA) to generate triplicate samples. A TotalPrep RNA Amplification Kit (Ambion, Austin, TX, USA) generated biotinylated cRNA, which was hybridized and analyzed on Illumina HumanHT-12v3 Beadchips (Illumina, San Diego, CA, USA) according to the manufacturer's protocol. Raw data underwent variancestabilizing transformation and quantile normalization using the Bioconductor Lumi package (Du et al., 2008) . Probes below background level (detection P-value o0.01) were excluded, and differential expression was identified with Bayes-adjusted variance analysis using the Bioconductor Limma package (Smyth, 2004) . Gene identifications were made using false-discovery rate-adjusted P-values of o0.05. Raw data are made available under Gene Expression Omnibus #18722.
Western blot analysis
Total cellular protein was extracted and blotted as described previously (Smalley et al., 2005) using antibody against human EGFR (Santa Cruz). After analysis, western blots were stripped once and reprobed for b-actin to assess even protein loading.
Statistical methods
Data points with error bars show means±standard error of mean (s.e.m.) based on triplicate values. Differences are analyzed between individual data points by paired Student's t-test and between curves by analysis of variance (ANOVA).
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